BBT-059 / Bolder BioTech - LARVOL DELTA

Longitudinal Serum Proteomic Profiling of Nonhuman Primates Exposed to Total-body Gamma Radiation and Treated with BBT-059. (PubMed, Radiat Res) - "These analyses revealed changes in proteins related to inflammation, innate immune activation, and hematological and platelet functions, which peaked at days 2 and 4 and gradually decreased to near baseline levels by the end of the study. Pathway enrichment analysis identified consistent activation of neutrophil degranulation, platelet degranulation, insulin-like growth factor transport, and calcium signaling pathways."

Journal • Hematological Disorders • Inflammation

Proteomic Studies in Rhesus Nonhuman Primates Administered a Promising Radiation Medical Countermeasure under Development, BBT-059. (PubMed, Radiat Res) - "Any dose of BBT-059 triggered a robust, acute-phase proteomic response characterized by an increase in platelet and neutrophil counts, elevated IL-6 expression, and an activation of the neutrophil degranulation and platelet activation, signaling and aggregation pathways. Taken together, these observations suggest that BBT-059 has a good safety profile for further development as a radiation MCM."

Journal • IL6